Telaprevir-based triple therapy for chronic hepatitis C patients with advanced fibrosis: A prospective clinical study

Alimentary Pharmacology and Therapeutics

Volumn 38, Issue 9, 2013, Pages 1076-1085

  Ogawa, E ^a   Furusyo, N ^a   Nakamuta, M ^b   Kajiwara, E ^c   Nomura, H ^d   Dohmen, K ^e   Takahashi, K ^f   Satoh, T ^g   Azuma, K ^h   Kawano, A ⁱ   Tanabe, Y ^j   Kotoh, K ^k   Shimoda, S ^k   Hayashi, J ^a  

^a KYUSHU UNIVERSITY HOSPITAL   (Japan)

^b NATIONAL HOSPITAL ORGANIZATION   (Japan)

^c STEEL MEMORIAL YAWATA HOSPITAL   (Japan)

^d Shin Kokura Hospital   (Japan)

^e CHIHAYA HOSPITAL   (Japan)

^f HAMANOMACHI HOSPITAL   (Japan)

^g Kokura Medical Center   (Japan)

^h KYUSHU CENTRAL HOSPITAL   (Japan)

ⁱ KITAKYUSHU MUNICIPAL MEDICAL CENTER   (Japan)

^j Fukuoka City Hospital   (Japan)

^k KYUSHU UNIVERSITY   (Japan)

more..

Author keywords

[No Author keywords available]

Indexed keywords

ALBUMIN; INOSINE TRIPHOSPHATASE; PEGINTERFERON ALPHA2B; PHOSPHATASE; RIBAVIRIN; TELAPREVIR; TELAVIC; UNCLASSIFIED DRUG; VIRUS RNA;

ACUTE KIDNEY FAILURE; ADULT; AGED; ALBUMIN BLOOD LEVEL; ALLELE; ANEMIA; ANOREXIA; ARTICLE; AUTOIMMUNE DISEASE; CELLULITIS; CLINICAL PRACTICE; CONTROLLED STUDY; CYTOPENIA; DISEASE ASSOCIATION; DISEASE SEVERITY; DRUG DOSE REDUCTION; DRUG EFFICACY; DRUG RESPONSE; DRUG SAFETY; DRUG WITHDRAWAL; FATIGUE; FEMALE; GENOTYPE; HEPATITIS C; HUMAN; INFECTION; INTERSTITIAL PNEUMONIA; JAPAN; LIVER FIBROSIS; LYMPHOMA; MAJOR CLINICAL STUDY; MALE; MULTICENTER STUDY; NEUTROPENIA; NONHUMAN; OTITIS MEDIA; PNEUMONIA; PRIORITY JOURNAL; PROSPECTIVE STUDY; RELAPSE; SKIN DISEASE; THROMBOCYTOPENIA; TREATMENT OUTCOME; URINARY TRACT INFECTION;

AGED; ANEMIA; ANTIVIRAL AGENTS; DRUG THERAPY, COMBINATION; FEMALE; GENOTYPE; HEPACIVIRUS; HEPATITIS C, CHRONIC; HUMANS; INTERFERON-ALPHA; LIVER CIRRHOSIS; MALE; MIDDLE AGED; OLIGOPEPTIDES; POLYETHYLENE GLYCOLS; PROSPECTIVE STUDIES; RECOMBINANT PROTEINS; RECURRENCE; RIBAVIRIN; TREATMENT OUTCOME;

EID: 84885127233     PISSN: 02692813     EISSN: 13652036     Source Type: Journal    
DOI: 10.1111/apt.12494     Document Type: Article

References (34)

1. Global Burden Of Hepatitis C Working Group. Global burden of disease (GBD) for hepatitis C. J Clin Pharmacol 2004; 44: 20-9.
2. Niederau C, Lange S, Heintges T, et al,. Prognosis of chronic hepatitis C: results of a large, prospective cohort study. Hepatology 1998; 28: 1687-95. (Pubitemid 28549142)
3. Ghany MG, Kleiner DE, Alter H, et al,. Progression of fibrosis in chronic hepatitis C. Gasatroenterology 2003; 124: 97-104. (Pubitemid 36055343)
4. Nishiguchi S, Kuroki T, Nakatani S, et al,. Randomised trial of effects of interferon-alpha on incidence of hepatocellular carcinoma in chronic active hepatitis C with cirrhosis. Lancet 1995; 346: 1051-5.
5. Morgan TR, Ghany MG, Kim HY, et al,. Outcome of sustained virological responders with histologically advanced chronic hepatitis C. Hepatology 2010; 52: 833-44.
6. Ogawa E, Furusyo N, Kajiwara E, et al,. Efficacy of pegylated interferon alpha-2b and ribavirin treatment on the risk of hepatocellular carcinoma in patients with chronic hepatitis C: a prospective, multicenter study. J Hepatol 2013; 58: 495-501.
7. European Association for the Study of the Liver. EASL Clinical Practice Guidelines: management of hepatitis C virus infection. J Hepatol 2011; 55: 245-64.
8. Furusyo N, Hayashi J, Ueno K, et al,. Human lymphoblastoid interferon treatment for patients with hepatitis C virus-related cirrhosis. Clin Ther 1997; 19: 1352-67. (Pubitemid 28133273)
9. Fried MW, Shiffman ML, Reddy KR,. Peginterferon alfa-2a plus ribavirin for chronic hepatitis C virus infection. N Engl J Med 2002; 347: 975-82.
10. Joshi D, Carey I, Agarwal K,. Review article: the treatment of genotype 1 chronic hepatitis C virus infection in liver transplant candidates and recipients. Aliment Pharmacol Ther 2013; 37: 659-71.
11. Zeuzem S, Andreone P, Pol S, et al,. Telaprevir for retreatment of HCV infection. N Engl J Med 2011; 364: 2417-28.
12. Jacobson IM, McHutchison JG, Dusheiko G, et al,. Telaprevir for previously untreated chronic hepatitis C virus infection. N Engl J Med 2011; 364: 2405-16.
13. Bacon BR, Gordon SC, Lawitz E, et al,. Boceprevir for previously treated chronic HCV genotype 1 infection. N Engl J Med 2011; 364: 1207-17.
14. Poordad F, McCone J Jr, Bacon BR, et al,. Boceprevir for untreated chronic HCV genotype 1 infection. N Engl J Med 2011; 364: 1195-206.
15. Hézode C, Fontaine H, Dorival C, et al,. Triple therapy in treatment-experienced patients with hcv-cirrhosis in a multicentre cohort of the french early access programme (anrs co20-cupic)-nct01514890. J Hepatol 2013; 59: 434-41.
16. Ogawa E, Furusyo N, Nakamuta M, et al,. Clinical milestones for the prediction of severe anaemia by chronic hepatitis C patients receiving telaprevir-based triple therapy. J Hepatol 2013; 59: 667-74.
17. Zeuzem S, Asselah T, Angus P, et al,. Efficacy of the protease inhibitor BI 201335, polymerase inhibitor BI 207127, and ribavirin in patients with chronic HCV infection. Gastroenterology 2011; 141: 2047-55.
18. Zeuzem S, Buggisch P, Agarwal K, et al,. The protease inhibitor, GS-9256, and non-nucleoside polymerase inhibitor tegobuvir alone, with ribavirin, or pegylated interferon plus ribavirin in hepatitis C. Hepatology 2012; 55: 749-58.
19. Tanaka Y, Nishida N, Sugiyama M, et al,. Genome-wide association of IL28B with response to pegylated interferon-alpha and ribavirin therapy for chronic hepatitis C. Nat Genet 2009; 41: 1105-9.
20. Ogawa E, Furusyo N, Murata M, et al,. Insulin resistance undermines the advantages of IL28B polymorphism in the pegylated interferon alpha-2b and ribavirin treatment of chronic hepatitis C patients with genotype 1. J Hepatol 2012; 57: 534-40.
21. Furusyo N, Ogawa E, Sudoh M, et al,. Raloxifene hydrochloride is an adjuvant antiviral treatment of postmenopausal women with chronic hepatitis C: a randomized trial. J Hepatol 2012; 57: 1186-92.
22. Fellay J, Thompson AJ, Ge D, et al,. ITPA gene variants protect against anaemia in patients treated for chronic hepatitis C. Nature 2010; 464: 405-8.
23. The French METAVIR Cooperative Study Group. Intraobserver and interobserver variations in liver biopsy interpretation in patients with chronic hepatitis C. Hepatology 1994; 20: 15-20.
24. Ogawa E, Furusyo N, Murata M, et al,. Early phase viral kinetics of chronic hepatitis C patients receiving telaprevir-based triple therapy: a comparison of two real-time PCR assays. Antiviral Res 2013; 99: 119-24.
25. Simmonds P, Alberti A, Alter HJ, et al,. A proposed system for the nomenclature of hepatitis C viral genotypes. Hepatology 1994; 19: 1321-4. (Pubitemid 24134259)
26. Furusyo N, Ogawa E, Nakamuta M, et al,. Telaprevir can be successfully and safely used to treat older patients with genotype 1b chronic hepatitis C. J Hepatol 2013; 59: 205-12.
27. Gordon SC, Yoshida EM, Lawitz EJ, et al,. Adherence to assigned dosing regimen and sustained virological response among chronic hepatitis C genotype 1 patients treated with boceprevir plus peginterferon alfa-2b/ribavirin. Aliment Pharmacol Ther 2013; 38: 16-27.
28. Furusyo N, Ogawa E, Murata M, et al,. Therapeutic drug monitoring of telaprevir in chronic hepatitis C patients receiving telaprevir-based triple therapy is useful for predicting virological response. J Antimicrob Chemother 2013; 99: 119-24.
29. Rowe IA, Houlihan DD, Mutimer DJ,. Despite poor interferon response in advanced hepatitis C virus infection, models of protease inhibitor treatment predict maximum treatment benefit. Aliment Pharmacol Ther 2012; 36: 670-9.
30. Ramachandran P, Fraser A, Agarwal K, et al,. UK consensus guidelines for the use of the protease inhibitors boceprevir and telaprevir in genotype 1 chronic hepatitis C infected patients. Aliment Pharmacol Ther 2012; 35: 647-62.
31. Leroy V, Serfaty L, Bourlière M, et al,. Protease inhibitor-based triple therapy in chronic hepatitis C: guidelines by the French Association for the Study of the Liver. Liver Int 2012; 32: 1477-92.
32. Sherman KE, Flamm SL, Afdhal NH, et al,. Response-guided telaprevir combination treatment for hepatitis C virus infection. N Engl J Med 2011; 365: 1014-24.
33. Sarrazin C, Kieffer TL, Bartels D, et al,. Dynamic hepatitis C virus genotypic and phenotypic changes in patients treated with the protease inhibitor telaprevir. Gastroenterology 2007; 132: 1767-77. (Pubitemid 46677938)
34. Vera-Llonch M, Martin M, Aggarwal J, et al,. Health-related quality of life in genotype 1 treatment-naïve chronic hepatitis C patients receiving telaprevir combination treatment in the ADVANCE study. Aliment Pharmacol Ther 2013; 38: 124-33.